One rigorous deep-dive every couple of weeks on longevity, cellular reprogramming and peptides — in plain language, with the line between proven and merely promising stated outright.
A thousand words on a single question, read end to end in under ten minutes. No link roundups, no news recaps, no “five things I’m thinking about”.
Established, promising or speculative — marked in the margin, so you always know whether you’re reading a result or a hypothesis.
Where evidence supports doing something differently, we say so plainly. Where it doesn’t — which is more often — we say that instead.
The Frontier is written by a researcher, not a copywriter. Each issue starts from the primary literature — the paper, its methods section, its sample size — and is checked against a second reviewer before it goes out.
It is published by Origin Health, which sells research compounds. That is a conflict of interest, so we handle it the only honest way: nothing in The Frontier links to a product, recommends a compound to buy, or mentions a price. If an issue concludes the evidence is weak for something Origin sells, the issue still says so.
Cellular reprogramming, senolytics, GLP-1s, sleep, peptides — whatever the literature actually supports this fortnight.